Expression of a specific extracellular matrix signature is a favorable prognostic factor in acute myeloid leukemia

Valerio Izzi; Juho Lakkala; Raman Devarajan; Eeva-Riitta Savolainen; Pirjo Koistinen; Ritva Heljasvaara; Taina Pihlajaniemi

Leukemia Research Reports (Jan 2018)

Expression of a specific extracellular matrix signature is a favorable prognostic factor in acute myeloid leukemia

Valerio Izzi,
Juho Lakkala,
Raman Devarajan,
Eeva-Riitta Savolainen,
Pirjo Koistinen,
Ritva Heljasvaara,
Taina Pihlajaniemi

Affiliations

Valerio Izzi: Centre of Excellence in Cell-Extracellular Matrix Research and Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland; Correspondence to: Center for Cell-Matrix Research, Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine, P.O. Box 5000, FIN-90014 University of Oulu, Finland.
Juho Lakkala: Centre of Excellence in Cell-Extracellular Matrix Research and Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland
Raman Devarajan: Centre of Excellence in Cell-Extracellular Matrix Research and Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland
Eeva-Riitta Savolainen: Nordlab Oulu and Institute of Diagnostics, Department of Clinical Chemistry, Oulu University Hospital, University of Oulu, Oulu, Finland
Pirjo Koistinen: Medical Research Center Oulu, Institute of Clinical Medicine, Oulu University Hospital, University of Oulu, Oulu, Finland
Ritva Heljasvaara: Centre of Excellence in Cell-Extracellular Matrix Research and Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland; Centre for Cancer Biomarkers (CCBIO), Department of Biomedicine, University of Bergen, N-5009 Bergen, Norway
Taina Pihlajaniemi: Centre of Excellence in Cell-Extracellular Matrix Research and Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland

Journal volume & issue: Vol. 9
pp. 9 – 13

Abstract

Read online

Relapse of acute myeloid leukemia (AML) is still dramatically frequent, imposing the need for early markers to quantify such risk. Recent evidence point to a prominent role for extracellular matrix (ECM) in AML, but its prognostic value has not yet been investigated. Here we have investigated whether the expression of a 15-ECM gene signature could be applied to clinical AML research evaluating a retrospective cohort of 61 AML patients and 12 healthy donors. Results show that patients whose ECM signature expression is at least twice as that of healthy donors have considerably longer relapse-free survival, with further stage-specific therapy outcomes. Keywords: Extracellular matrix (ECM), Acute myeloid leukemia (AML), Hematopoiesis, Clinical study, PCR

Published in Leukemia Research Reports

ISSN: 2213-0489 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.journals.elsevier.com/leukemia-research-reports/

About the journal